Closure Medical adopts rights plan:
This article was originally published in Clinica
Closure Medical, which develops and manufactures adhesive products based on its proprietary cyanoacrylate technology for wound closure, has put in place a shareholder rights plan. The plan is activated if a third party acquires 15% or more of the company or announces a tender amount for that amount. "We believe that the plan protects stockholder interests in the event that the company is confronted with coercive or unfair takeover tactics, including offers that do not treat all stockholder interests fairly or do not maximise the value of the company," said Robert Toni, president and CEO of the Raleigh, North Carolina-based company.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.